{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:50Z","timestamp":1740144230401,"version":"3.37.3"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Percutaneous coronary intervention with the new generation drug eluting stents (DES) is 1 among the revascularization procedures required to treat patients with coronary artery disease (CAD). Since late stent thrombosis and silent myocardial infarction are highly associated with type 2 diabetes mellitus (T2DM), an analysis comparing the newer generation DES in this specific subgroup of patients would be scientifically relevant.<\/jats:p>\n            <jats:p>In this analysis, we aimed to systematically compare the cardiovascular outcomes observed with the ultrathin bioresorbable polymer sirolimus eluting stents (SES) versus thin, durable polymer everolimus eluting stents (EES) following percutaneous coronary intervention in patients with T2DM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Through online databases, relevant studies comparing ultrathin bioresorbable polymer SES versus the durable polymer EES were carefully searched. The cardiovascular outcomes were assessed during a follow-up time period of 1 year and more than 1 year (1\u20135 years) respectively. This meta-analysis was carried out by the latest version of the RevMan software. Following analysis, the results were represented by odds ratios (OR) with 95% confidence intervals (CI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total number of 1967 patients with T2DM were included in this analysis. During a 1 year follow-up time period, target lesion failure (TLF) (OR: 0.59, 95% CI: 0.34\u20131.02; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.06, target vessel revascularization (TVR) (OR: 0.97, 95% CI: 0.55\u20131.70; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.91) and target lesion revascularization (TLR) (OR: 0.91, 95% CI: 0.44\u20131.87; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.79) were similarly observed with ultrathin bioresorbable polymer SES versus the thin, durable polymer EES in these patients with T2DM. Other cardiovascular outcomes including myocardial infarction (MI), major adverse cardiac events, all-cause mortality (OR: 0.72, 95% CI: 0.37\u20131.40; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.34), cardiac death and stent thrombosis (OR: 0.85, 95% CI: 0.45\u20131.62; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.63) were also similarly observed with these 2 types of new stents. During a follow-up time period above 1 year (1\u20135 years), still no significant difference was observed in TLF, TVR, TLR, major adverse cardiac events, MI, all-cause mortality, cardiac death and stent thrombosis (OR: 0.62, 95% CI: 0.33\u20131.16; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.14).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The ultrathin bioresorbable polymer SES were similar to the durable polymer EES in these patients with T2DM. These 2 types of new generation stents were comparable in terms of cardiovascular outcomes. Hence, they might be recommended in patients with T2DM. Upcoming trials should be able to confirm this hypothesis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023810","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T10:04:04Z","timestamp":1608631444000},"page":"e23810","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular outcomes associated with Ultrathin bioresorbable polymer sirolimus eluting stents versus thin, durable polymer everolimus eluting stents following percutaneous coronary intervention in patients with type 2 diabetes mellitus"],"prefix":"10.1097","volume":"99","author":[{"given":"Shibing","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, The First Clinical Medical College of Yangtze University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuying","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The First People's Hospital of Jingzhou, Jingzhou, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5463-2789","authenticated-orcid":false,"given":"Zhiming","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The First Clinical Medical College of Yangtze University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(15)61220-X","article-title":"Stable coronary artery disease: revascularisation and invasive strategies","volume":"386","author":"Piccolo","year":"2015","journal-title":"Lancet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/CIRCULATIONAHA.106.683995","article-title":"Late coronary stent thrombosis","volume":"116","author":"Windecker","year":"2007","journal-title":"Circulation"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"g3859","DOI":"10.1136\/bmj.g3859","article-title":"Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis","volume":"348","author":"Windecker","year":"2014","journal-title":"BMJ"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW\u200aV): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1871530319666191014110414","article-title":"A review on the effects of new anti-diabetic drugs on platelet function","volume":"20","author":"Yaribeygi","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40256-018-0295-y","article-title":"Early and late stent thrombosis in patients with versus without diabetes mellitus following percutaneous coronary intervention with drug-eluting stents: a systematic review and meta-analysis","volume":"18","author":"Yuan","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/j.jacc.2018.09.019","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents","volume":"72","author":"Kandzari","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.amjcard.2015.11.044","article-title":"Comparison of the absorbable polymer sirolimus-eluting stent (MiStent) to the durable polymer everolimus-eluting stent (Xience) (from the DESSOLVE I\/II and ISAR-TEST-4 Studies)","volume":"117","author":"Lansky","year":"2016","journal-title":"Am J Cardiol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II Trial","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial","volume":"392","author":"Pilgrim","year":"2018","journal-title":"Lancet"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"e007331","DOI":"10.1161\/CIRCINTERVENTIONS.118.007331","article-title":"Subgroup analysis comparing ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in acute coronary syndrome patients","volume":"11","author":"Roguin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e006741","DOI":"10.1161\/CIRCINTERVENTIONS.118.006741","article-title":"Unselected use of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for coronary revascularization","volume":"11","author":"Yamaji","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MCA.0000000000000797","article-title":"Comparison of efficacy and safety between ultrathin bioresorbable polymer sirolimus-eluting stents and thin durable polymer drug-eluting stents: a systematic review and meta-analysis of the literature","volume":"30","author":"Zhai","year":"2019","journal-title":"Coron Artery Dis"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.amjcard.2019.06.021","article-title":"Efficacy and safety of ultrathin, bioresorbable-polymer sirolimus-eluting stents versus thin, durable-polymer everolimus-eluting stents for coronary revascularization of patients with diabetes mellitus","volume":"124","author":"Waksman","year":"2019","journal-title":"Am J Cardiol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1161\/JAHA.116.003255","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial","volume":"5","author":"Zbinden","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:46:05Z","timestamp":1694828765000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023810"}},"subtitle":["A meta-analysis of published studies"],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":18,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023810","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}